Research Articles

• Tsai, A.K., Cruz-Hinojoza, E., Ellefson, M.A., Burrack, A.L., Larsen, B.M., Martinez, R.J. and Stromnes, I.M., 2025. Maturation of thymocytes with a monoclonal TCR under control of Trac promoter elements in the absence of β-selection. ImmunoHorizons, 9(8), p.vlaf035.

• Schmiechen, Z.C., Nanda, H.A., Burrack, A.L., Hickok, G.H., Butler, J.Z., Cruz-Hinojoza, E., Maurice, N.J., Geuenich, M.J., Yu, C., Tsai, A.K. and Lonetree, C.L.  Shen, S. & Stromnes I.M. , 2025. IL-15 complex enhances agonistic anti-CD40+ anti-PDL1 by correcting the T-bet to Tox ratio in CD8+ T cells infiltrating pancreatic ductal adenocarcinoma. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.CIR-24-0758 

• Rollins, M. R., Raynor, J. F., Miller, E. A., Butler, J. Z., Spartz, E. J., Lahr, W. S., You, Y., Burrack, A. L., Moriarity, B. S., Webber, B. R., & Stromnes, I. M. 2023. Germline T cell receptor exchange results in physiological T cell development and function. Nature Communications, 14(1), 528. https://doi.org/10.1038/s41467-023-36180-1

• Burrack, A.L., Spartz, E.J., Rollins, M.R., Miller, E.A., Firulyova, M., Cruz, E., Goldberg, M.F., Wang, I.X., Nanda, H., Shen, S., Zaitsev, K., Stromnes, I.M. 2022. Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate. Cancer Immunology, Immunotherapy, pp.1-18. https://doi.org/10.1007/s00262-022-03338-7

• Burrack, A. L., Schmiechen, Z. C., Patterson, M. T., Miller, E. A., Spartz, E. J., Rollins, M. R., Raynor, J. F., Mitchell, J. S., Kaisho, T., Fife, B. T., & Stromnes, I. M. 2022. Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer. JCI Insight, 7(7). https://doi.org/10.1172/jci.insight.151593

• Stromnes, I.M., Hulbert, A., Rollins, M.R., Basom, R.S., Delrow, J., Bonson, P., Burrack, A.L., Hingorani, S.R. and Greenberg, P.D., 2022. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer. Journal for Immunotherapy of Cancer, 10(2). http://dx.doi.org/10.1136/jitc-2021-003525

• Burrack, AB, Rollins, M, Spartz, EH, Mesojednik, TD, Schmiechen, ZC, Wang, IX, Raynor, JF, Kedl, R, and Stromnes IM. CD40 agonist overcomes T cell exhaustion induced by chronic myeloid cell IL-27 production in a pancreatic cancer preclinical model. Journal of Immunology, 2021 https://www.jimmunol.org/content/206/6/1372

• Rollins, M, Spartz, EH, and Stromnes IM. T cell receptor engineered lymphocytes for adoptive cell therapy. Current Protocols in Immunology. V 129 (1):e97, 2020 https://currentprotocols.onlinelibrary.wiley.com/doi/full/10.1002/cpim.97

• Burrack, AB, Spartz, EH, Raynor, JF, Wang, Iris, Olson, M and Stromnes IM. Combination PD-1 and PD-L1 blockade promotes durable neoantigen-specific T cell-mediated immunity in pancreatic ductal adenocarcinoma. Cell Reports, 2019 https://pubmed.ncbi.nlm.nih.gov/31433988/

• Anderson, KG, Voillet, V, Bates, BM, Chiu, EY, Burnett, MG, Garcia, N, Oda, S, Morse, CB, Stromnes, I., Drescher, CW, Gottardo, R and Greenberg, P. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. Cancer Immunology Research, 2019 https://cancerimmunolres.aacrjournals.org/content/7/9/1412

• Stromnes IM, Burrack A, Hulbert A, Black C, Bonson P, Raynor J, Spartz, E, Pierce RH, Hingorani SR and Greenberg PD. Differential effects of depleting versus programming tumor-associated macrophages on engineered T cells in pancreatic ductal adenocarcinoma. Cancer Immunology Research 2019, https://pubmed.ncbi.nlm.nih.gov/31028033/

• Stromnes, IM et al., T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunology Research, 2017 https://www.ncbi.nlm.nih.gov/pubmed/29066497

• Anderson KA, Stromnes IM and Greenberg, PD. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell, 2017 https://www.ncbi.nlm.nih.gov/pubmed/28292435

• Stromnes IM et al., T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2015 https://www.ncbi.nlm.nih.gov/pubmed/26525103

• Stromnes IM et al. Molecular Pathways: Myeloid complicity in cancer. Clinical Cancer Research. https://www.ncbi.nlm.nih.gov/pubmed/25047706

• Stromnes IM et al., Stromal reengineering to treat pancreas cancer. Carcinogenesis, 2014 https://www.ncbi.nlm.nih.gov/pubmed/24908682

• Stromnes IM et al, Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut, 2014 https://www.ncbi.nlm.nih.gov/pubmed/24555999

• Stromnes IM et al., Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunology Reviews, 2014 https://www.ncbi.nlm.nih.gov/pubmed/24329795

• Schmitt TM, Aggen DH, Stromnes IM, Dossett ML, Richman SA, Kranz DM, Greenberg PD. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood, The Journal of the American Society of Hematology. 2013  https://www.ncbi.nlm.nih.gov/pubmed/23673862